This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

BELLUS Health Future Growth

Future criteria checks 2/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for BELLUS Health.

Key information

46.1%

Earnings growth rate

41.4%

EPS growth rate

Biotechs earnings growth	34.3%
Revenue growth rate	69.0%
Future return on equity	n/a
Analyst coverage	Low
Last updated	16 Jun 2023

Recent future growth updates

Recent updates

BELLUS Health (TSE:BLU) Is In A Good Position To Deliver On Growth Plans

Jan 16

Here's Why We're Not Too Worried About BELLUS Health's (TSE:BLU) Cash Burn Situation

Sep 07

Earnings and Revenue Growth Forecasts

TSX:BLU - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	40	-147	-110	-64	3
12/31/2024	0	-141	-130	-127	3
12/31/2023	0	-117	-125	-101	2
3/31/2023	0	-87	-89	-89	N/A
12/31/2022	0	-76	-77	-77	N/A
9/30/2022	0	-73	-68	-68	N/A
6/30/2022	0	-71	-64	-64	N/A
3/31/2022	0	-70	-60	-60	N/A
12/31/2021	0	-71	-61	-61	N/A
9/30/2021	0	-64	-49	-49	N/A
6/30/2021	0	-47	-40	-40	N/A
3/31/2021	0	-37	-36	-36	N/A
12/31/2020	0	-32	-30	-30	N/A
9/30/2020	0	-34	-30	-30	N/A
6/30/2020	0	-35	-32	-32	N/A
3/31/2020	0	-33	-29	-29	N/A
12/31/2019	0	-26	-21	-21	N/A
9/30/2019	0	-18	-14	-14	N/A
6/30/2019	0	-14	-9	-9	N/A
3/31/2019	0	-9	-8	-8	N/A
12/31/2018	0	-7	-7	-7	N/A
9/30/2018	0	-6	-7	-7	N/A
6/30/2018	0	-5	-6	-6	N/A
3/31/2018	0	-4	-5	-5	N/A
12/31/2017	0	-1	-5	-3	N/A
9/30/2017	0	-1	-4	-3	N/A
6/30/2017	1	0	-3	-2	N/A
3/31/2017	1	0	-3	-2	N/A
12/31/2016	1	-2	N/A	-2	N/A
9/30/2016	3	-1	N/A	-2	N/A
6/30/2016	3	0	N/A	-2	N/A
3/31/2016	3	0	N/A	-2	N/A
12/31/2015	3	0	N/A	-2	N/A
9/30/2015	2	0	N/A	-2	N/A
6/30/2015	2	-1	N/A	-2	N/A
3/31/2015	2	-1	N/A	-2	N/A
12/31/2014	2	-2	N/A	-3	N/A
9/30/2014	2	-2	N/A	-3	N/A
6/30/2014	2	-1	N/A	-4	N/A
3/31/2014	2	-1	N/A	-3	N/A
12/31/2013	2	-1	N/A	-3	N/A
9/30/2013	2	-1	N/A	-3	N/A
6/30/2013	2	-2	N/A	-3	N/A
3/31/2013	2	-10	N/A	-3	N/A
12/31/2012	2	-13	N/A	-3	N/A
9/30/2012	3	-15	N/A	-2	N/A
6/30/2012	3	-14	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BLU is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BLU is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BLU is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BLU's revenue (69% per year) is forecast to grow faster than the Canadian market (5.3% per year).

High Growth Revenue: BLU's revenue (69% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BLU's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/06/28 03:33
End of Day Share Price	2023/06/28 00:00
Earnings	2023/03/31
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BELLUS Health Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Brian Skorney	Baird
Justin Zelin	BTIG
Pooya Hemami	Edison Investment Research

This company has been acquired

BELLUS Health Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus revenue estimates increase by 40%, EPS downgraded

Consensus revenue estimates decrease by 22%, EPS upgraded

Price target decreased by 30% to CA$14.75

Consensus revenue estimates fall by 93%

Price target increased to CA$18.50

Consensus revenue estimates increase by 56%

Recent updates

BELLUS Health Inc.(NasdaqGS:BLU) dropped from NASDAQ Composite Index

GSK plc (LSE:GSK) completed the acquisition of BELLUS Health Inc. (TSX:BLU).

President exercised options to buy CA$35m worth of stock.

Consensus revenue estimates increase by 40%, EPS downgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates decrease by 22%, EPS upgraded

Price target decreased by 30% to CA$14.75

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

BELLUS Health (TSE:BLU) Is In A Good Position To Deliver On Growth Plans

Insufficient new directors

Independent Lead Director recently sold CA$449k worth of stock

President exercised options and sold CA$3.1m worth of stock

Independent Director recently sold CA$433k worth of stock

Consensus revenue estimates fall by 93%

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We're Not Too Worried About BELLUS Health's (TSE:BLU) Cash Burn Situation

First half 2022 earnings released

BELLUS Health Inc. Expects to Initiate A Phase 1 Clinical Trial Investigating A Once-Daily, Extended-Release Formulation of BLU-5937 in the Fourth Quarter of 2022

Bellus Health Inc. Announces Positive End-Of-Phase 2 Meeting with the FDA and Its Calm Phase 3 Program for BLU-5937 in Refractory Chronic Cough

Price target increased to CA$18.50

Consensus revenue estimates increase by 56%

We're Hopeful That BELLUS Health (TSE:BLU) Will Use Its Cash Wisely

Senior Vice President of Finance recently sold CA$576k worth of stock

Chief Scientific Officer recently sold CA$951k worth of stock

BELLUS Health Inc., Annual General Meeting, May 11, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Consensus forecasts updated

Consensus revenue estimates increase by 16%

Here's Why We're Watching BELLUS Health's (TSE:BLU) Cash Burn Situation

Bellus Health Announces Positive Topline Results from Its Phase 2B Soothe Trial of Blu-5937 for the Treatment of Refractory Chronic Cough

Price target increased to CA$16.40

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.094 loss in 3Q 2020)

BELLUS Health Inc. Announces Completion of Patient Enrollment in Soothe Phase 2B Trial for Refractory Chronic Cough and Blueprint Phase 2A Trial for Chronic Pruritus Associated with Atopic Dermatitisz

BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough

Price target increased to CA$10.70

Companies Like BELLUS Health (TSE:BLU) Are In A Position To Invest In Growth